CYP450-GP

Executive Summary

CYP450-GP is a San Diego-based provider of monospecific, inhibitory cytochrome P450 antibodies designed for P450 reaction phenotyping studies, a critical step in drug metabolism research. The company’s flagship product, the CYP Immunoinhibition Kit, includes antibodies targeting the six most prevalent drug-metabolizing P450 enzymes, enabling researchers to accurately identify which enzymes are responsible for drug metabolism. Founded in 2015, the company operates in the diagnostics and research tools segment, serving pharmaceutical and academic laboratories. As a private entity with no disclosed funding or revenue, CYP450-GP occupies a niche but essential role in the drug development pipeline, where understanding metabolic pathways is crucial for safety and efficacy assessments. The company’s tools help streamline preclinical studies, reducing the risk of adverse drug interactions and supporting regulatory submissions. With a small product portfolio and no publicly disclosed pipeline, the company’s growth is tied to market adoption of its kits and potential expansion into related areas, such as custom antibody development or integrated assay services. The competitive landscape includes larger players like Corning and Thermo Fisher, but CYP450-GP’s specialized focus on inhibitory antibodies offers a differentiated value proposition. Near-term catalysts include product line extensions, strategic partnerships, and increased awareness through scientific publications or conference presentations.

Upcoming Catalysts (preview)

• Q3 2026Launch of expanded CYP antibody panel covering additional P450 isozymes60% success
• Q4 2026Strategic partnership or distribution agreement with a major life sciences tools company40% success
• Q2 2026First major publication validating the CYP Immunoinhibition Kit in a high-impact journal50% success